The Government of India has implemented new restrictions regarding Fixed Dose Combinations (FDCs) that include the active ingredients Chlorpheniramine Maleate and Phenylephrine Hydrochloride. This initiative aims to protect the health and safety of children below the age of four years. The directive highlights that these medications are not to be used in this age group, necessitating compliance from manufacturers, distributors, and healthcare providers.

Background of the Legislation

This latest regulation expands upon earlier restrictions issued on April 15, which similarly pertained to certain combinations of Chlorpheniramine and Phenylephrine. The prior notification already required necessary age-specific warnings, but the current update broadens the scope to encompass all formulations containing these ingredients. Such actions are grounded in the recommendations made by an Expert Committee and the Drugs Technical Advisory Board (DTAB), aimed at minimising potential health risks for very young children.

The Government’s analysis revealed that these specific combinations could carry risks that are detrimental to children under four. Officials have also noted that safer alternative medications are available, contributing to the rationale for this new prohibition.

Regulatory compliance is essential in this matter, and manufacturers are now obliged to include clear warnings on product labels, package inserts, and promotional materials. The critical message—“Fixed Dose Combination shall not be used in children below four years of age”—must be prominently displayed to ensure that caregivers are adequately informed about the risks.

Implementation of Public Health Notification

This recent announcement from the Ministry of Health and Family Welfare was issued under Section 26A of the Drugs and Cosmetics Act, 1940. It underscores the Government’s commitment to safeguarding public health, particularly among vulnerable populations like young children. The regulation is in effect from the date of its publication in the Official Gazette, signalling the urgency of adherence by all stakeholders involved.

The authorities have communicated the significance of these warnings to healthcare providers, pharmacies, and hospitals, ensuring that everyone involved in the distribution and administration of such medications is aware of the new standards. It is crucial that proper precautions are taken to avoid any adverse effects on young patients.

Further monitoring will be essential to observe compliance with the regulation. The Ministry has pledged ongoing efforts to assess the safety profiles of medications prescribed to children, thereby reinforcing its position on preventive healthcare measures. This push for regulation aligns with broader public health objectives aimed at enhancing the well-being of children across the country.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share